Serum human neutrophil lipocalin as a diagnostic biomarker for bacterial infections in tumor patients
Frontiers in Cellular and Infection Microbiology · 20.11.2026 · 16
DOI: 10.3389/fcimb.2026.1921858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 20.11.2026. Verfasst von Yajun Miao und 2 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tumor patients undergoing chemoradiotherapy are highly susceptible to bacterial infections. This study evaluated the diagnostic performance of inflammatory biomarkers for bacterial infections in tumor patients.
Methods
In this study, 333 tumor patients were enrolled, including 168 in the bacterial infection group and 165 in the control group. For evaluation of diagnostic value, these patients were divided into a training set (n = 233) and a validation set (n = 100). Serum levels of human neutrophil lipocalin (HNL), procalcitonin (PCT), prealbumin (PA), and routine hematological indices were measured. Diagnostic efficacy was assessed using receiver operating characteristic (ROC) analysis, and the final biomarker combination was identified via binary logistic regression. Pre-specified subgroup analyses were performed to assess pathogen-type discrimination across Gram-negative and Gram-positive infections, and antimicrobial resistance patterns were also evaluated.
Results
Infected patients exhibited significantly elevated HNL (257.4 vs 164.2 ng/mL, P < 0.001), PCT (0.34 vs 0.11 μg/L, P < 0.001), white blood cell (WBC), neutrophils (NEU), D-dimer, and systemic inflammation indices including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), with reduced PA (0.146 vs 0.188 g/L) and lymphocytes (LYM) (0.82 vs 0.97 × 10 9 /L) (all P < 0.05). HNL (AUC = 0.858) and PCT (AUC = 0.827) demonstrated good individual diagnostic performance. The combination of HNL, PCT, and PA constituted the final diagnostic model (AUC = 0.919 in cross-validation; sensitivity 87%, specificity 95%), with acceptable calibration and favorable decision curve analysis. In an exploratory analysis, PCT levels were significantly higher in Gram-negative than in Gram-positive bacterial infections (0.41 vs 0.145 μg/L, P < 0.001), with an AUC of 0.807 and an exploratory cutoff value of 0.195 μg/L.
Conclusions
The results demonstrated that HNL exhibited good diagnostic performance, and the combination of HNL, PCT, and PA constituted the final diagnostic model for these infections. Furthermore, PCT showed potential value in distinguishing between Gram-negative and Gram-positive bacterial infections. Collectively, these findings may provide useful information for selecting inflammatory biomarkers in diagnosing bacterial infections among tumor patients, while external validation is warranted.
Zitieren
APA
Miao, Y., Zhang, W., & Liu, L. (2026). Serum human neutrophil lipocalin as a diagnostic biomarker for bacterial infections in tumor patients. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1921858
Vancouver
Miao Y, Zhang W, Liu L. Serum human neutrophil lipocalin as a diagnostic biomarker for bacterial infections in tumor patients. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1921858
BibTeX
@article{Miao2026,
author = {Miao, Yajun and Zhang, Weiwei and Liu, Lisheng},
title = {Serum human neutrophil lipocalin as a diagnostic biomarker for bacterial infections in tumor patients},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1921858}
}
EUVIMED